At 3 years, the men in the spacer arm had decreased bowel toxicity and fewer declines in both urinary and bowel quality of life compared with the control group. In this secondary analysis of the phase III trial evaluated the attenuation of the decline in sexual function as a result of using a hydrogel spacer (SpaceOAR System) placed between the prostate and rectum during IMRT. Sexual QOL was measured with the Expanded Prostate Cancer Index Composite (EPIC) score. The authors concluded that the use of the SapceOAR hydrogel spacer decreased dose to the penile bulb with a suggestion of a clinically significant improvement in patient reported sexual function and potency. These did not achieve statistical significance potentially due to the high prevalence of ED at baseline and, therefore, the small evaluable sample size. Analysis of penile bulb dose and QOL is ongoing. Clinical trial information: NCT01538628.
J Clin Oncol 35, 2017 (suppl 6S; abstract 69)
Presented by: Daniel A. Hamstra MD, PhD , Assistant Professor, Radiation Oncology, University of Michigan, Ann Arbor
Roger Li MD, Urologic Oncology Fellow, Department of Urology, UT MD Anderson Cancer Center, Houston, TX
Ashish M. Kamat, MD, MBBS, FACS, Wayne B. Duddlesten Professor, Department of Urology, UT MD Anderson Cancer Center, Houston TX